Oligomerix names William Caple as board chairman

Oligomerix Inc., a clinical-stage biotechnology company developing treatments for neurodegenerative diseases, announced the election of William Caple as chairman of its board of directors.

Caple brings over 30 years of executive leadership experience across multiple industries. He founded Caple Advisory Solutions, an international management consulting practice focused on growth, corporate finance, and business development. He currently serves on the board of Splash Beverage (NYSE American: SBEV) and is a member of The Livingston Group-Asia.

His previous experience includes leading the initial public offering of software company OTG Software (NASDAQ: OTGS) and representing Korean private equity firm Centroid Investment Partners in the $1.8 billion acquisition of TaylorMade Golf in 2021.

"I am very pleased to join Oligomerix as its Chairman at this critical stage of its development in Phase 1 clinical human testing," Caple said in the company's announcement.

The Bronx-based company is developing small molecule therapeutics targeting tau protein for Alzheimer's disease and rare neurodegenerative conditions including progressive supranuclear palsy and frontotemporal dementia. Its lead compound, OLX-07010, is currently in Phase 1 clinical trials as an oral, once-daily medication designed to prevent tau protein accumulation.

Oligomerix operates from the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine. The company stated it is seeking strategic partners to advance its clinical programs, according to the press release.

You May Also Be Interested In

• Splash Beverage Group to rename as Endovia Health Sciences on Aug. 21
• Xylem names Carlisle Companies CEO to its board of directors
• DeFi Technologies posts $7.8M revenue and $2.3M loss in Q2 2026